SQI Diagnostics Announces Agreement With Isis Pharmaceuticals, Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”) today announced that they have entered into a method development agreement with Isis Pharmaceuticals (Isis) to develop a multiplexed assay that will utilize SQI’s Ig_PLEX™ multiplexing immunogenicity technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news